Your session is about to expire
← Back to Search
MultiStem for Ischemic Stroke (MASTERS-2 Trial)
MASTERS-2 Trial Summary
This trial is testing whether an investigational stem cell product is safe and effective in treating adults who have had a stroke.
- Ischemic Stroke
- Stroke
MASTERS-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MASTERS-2 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has a study like this ever been conducted before?
"Since 2017, there has been ongoing research into MultiStem. The first clinical trial occurred in 2017 and was sponsored by Healios K.K. After the initial trial involving 220 people, MultiStem received approval for Phase 2 & 3 clinical trials. There are currently 4 active trials across 22 cities and 3 countries."
In how many different areas is this study being conducted?
"Patients are being accepted at the Athersys Investigational Site 127 in Sacramento, California, Athersys Investigational Site 102 in Portland, Oregon, Athersys Investigational Site 111 in Jackson, Mississippi, and 23 other locations."
What is the maximum number of people who can be a part of this test?
"That is correct, according to the latest information available on clinicaltrials.gov, this clinical trial is still looking for participants. 23 different medical centres are involved in the trial, and the goal is to have 300 patients total. The trial was first posted on July 28, 2018."
Are there other examples of MultiStem being used in research?
"Currently, there are 4 ongoing studies investigating MultiStem with 3 trials in Phase 3. While several of the trials for MultiStem are based in Phoenix, Arizona, there are 32 locations operating trials for MultiStem."
Are there any current vacancies for this research program?
"That is accurate. The clinical trial was posted on 7/28/2018 and was last updated on 2/8/2022. The trial is looking for 300 patients from 23 different sites."
Has the FDA cleared MultiStem for use in the United States?
"There is already some clinical data supporting the efficacy of MultiStem, as well as multiple rounds of data that suggest it is safe, so it received a score of 3."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger